[
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "We are wondering if it is safe to give buprenorphine without the naloxone [subutex] component. Select the statement(s) that are supported by evidence:\n\nI. Suboxone could be seen as less safe than Subutex because it contains naloxone, which is included to deter misuse by injection. Naloxone can precipitate withdrawal symptoms if the medication is injected, reducing the potential for abuse. \nII. Subutex could be seen as safer than Suboxone because it does not contain naloxone, which can cause withdrawal symptoms in some patients if they are sensitive to it or if the medication is misused. In certain clinical situations, such as in pregnant women or individuals with a known sensitivity to naloxone, Subutex may be preferred to avoid these potential issues. \nIII. Suboxone could be seen as similarly safe to Subutex because both medications contain buprenorphine, which is the primary active ingredient responsible for their therapeutic effects. The safety profile in terms of therapeutic use is similar when taken as prescribed. \nIV. We know there are a few cases where we can make a statement about its safety, but largely we don\u2019t know if Suboxone is safer than Subutex, though scientists are actively working to figure this out so we can be more correct in our prescriptions.\nV. The safety of Subutex versus Suboxone can be seen as dependent on the route of administration. Suboxone is designed to be safer in terms of reducing the risk of misuse when injected, due to the lack of naloxone, but when taken orally as prescribed, both medications have similar safety profiles.\n\n\nAnswer Choices:\nA. IV, V\nB. I, II, III\nC. I, II, IV\nD. III, IV\nE. I, IV\nF. III, IV, V\nG. I, V\nH. All of the options are correct.\nI. III, V\nJ. I, III, IV, V\nK. I, II, III, IV\nL. II, III, IV, V\nM. I, II\nN. II, IV\nO. I, II, V\nP. II, IV, V\nQ. II, III, V\nR. II, III\nS. I, II, IV, V\nT. II, V"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J",
                  "K",
                  "L",
                  "M",
                  "N",
                  "O",
                  "P",
                  "Q",
                  "R",
                  "S",
                  "T"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208130-iiKMM0IREyOF9sT6xId2",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"K. I, II, III, IV\\n\\nBrief rationale: Evidence supports that naloxone in Suboxone is intended to deter injection and can precipitate withdrawal if injected (I). Subutex (buprenorphine alone) has been preferred in some situations (e.g., pregnancy historically, or naloxone sensitivity) to avoid naloxone-related issues (II). When taken as prescribed (sublingually), both products\u2019 safety and efficacy are driven largely by buprenorphine and are broadly similar (III). There remains uncertainty and ongoing research about relative safety in some populations and routes of misuse, so broad, definitive superiority of one over the other is not established (IV). Statement V contains an incorrect phrase about \u201clack of naloxone\u201d in Suboxone and is therefore not supported as written.\",\"answer_letter\":\"K\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Clarifying medication safety**\n\nI'm exploring the uncertainty around the safety of Suboxone versus Subutex. There aren't many head-to-head trials, and the evidence seems mixed, indicating they're generally comparable. The statement that we don't know if Suboxone is safer than Subutex has some truth but feels a bit vague. It\u2019s been said that Suboxone is safer when injected because of its design, but that\u2019s misleading since Suboxone actually contains naloxone. The way this is presented seems confusing.**Analyzing medication safety statements**\n\nI think the intention was to suggest that Suboxone is designed to reduce misuse risk when injected due to naloxone. However, this creates an error because it implies a \"lack of naloxone,\" which isn't true. Both medications are similar when taken sublingually, making the safety depend on the route of administration. Options I, II, III, and IV seem largely supported, except I\u2019s initial phrase might need reworking. Option K includes all supported statements, which seems like the best choice.**Finalizing the answer**\n\nI\u2019m reflecting on the statement about Suboxone being \"less safe\" due to naloxone. While naloxone does create the risk of precipitated withdrawal if misused, it's also effective in deterring misuse. So, I feel III is supported, and IV is okay too. Comparing options, K looks best since it includes I, III, and IV while excluding flawed statements like V. I should definitely provide a succinct justification discussing evidence, which includes how naloxone works and the safety comparisons. Let's craft the answer in the required format!",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Clarifying medication safety**\n\nI'm exploring the uncertainty around the safety of Suboxone versus Subutex. There aren't many head-to-head trials, and the evidence seems mixed, indicating they're generally comparable. The statement that we don't know if Suboxone is safer than Subutex has some truth but feels a bit vague. It\u2019s been said that Suboxone is safer when injected because of its design, but that\u2019s misleading since Suboxone actually contains naloxone. The way this is presented seems confusing.**Analyzing medication safety statements**\n\nI think the intention was to suggest that Suboxone is designed to reduce misuse risk when injected due to naloxone. However, this creates an error because it implies a \"lack of naloxone,\" which isn't true. Both medications are similar when taken sublingually, making the safety depend on the route of administration. Options I, II, III, and IV seem largely supported, except I\u2019s initial phrase might need reworking. Option K includes all supported statements, which seems like the best choice.**Finalizing the answer**\n\nI\u2019m reflecting on the statement about Suboxone being \"less safe\" due to naloxone. While naloxone does create the risk of precipitated withdrawal if misused, it's also effective in deterring misuse. So, I feel III is supported, and IV is okay too. Comparing options, K looks best since it includes I, III, and IV while excluding flawed statements like V. I should definitely provide a succinct justification discussing evidence, which includes how naloxone works and the safety comparisons. Let's craft the answer in the required format!",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "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",
                "id": "rs_06ce5f268a17ad260169092982d68c8195a827cda8887658ed",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208130,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 1336,
        "prompt_tokens": 563,
        "total_tokens": 1899,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 1152,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00281275,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 0.00014075,
          "upstream_inference_completions_cost": 0.002672
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "We are wondering if it is safe to give buprenorphine without the naloxone [subutex] component. Select the statement(s) that are supported by evidence:\n\nI. Suboxone could be seen as less safe than Subutex because it contains naloxone, which is included to deter misuse by injection. Naloxone can precipitate withdrawal symptoms if the medication is injected, reducing the potential for abuse. \nII. Subutex could be seen as safer than Suboxone because it does not contain naloxone, which can cause withdrawal symptoms in some patients if they are sensitive to it or if the medication is misused. In certain clinical situations, such as in pregnant women or individuals with a known sensitivity to naloxone, Subutex may be preferred to avoid these potential issues. \nIII. Suboxone could be seen as similarly safe to Subutex because both medications contain buprenorphine, which is the primary active ingredient responsible for their therapeutic effects. The safety profile in terms of therapeutic use is similar when taken as prescribed. \nIV. We know there are a few cases where we can make a statement about its safety, but largely we don\u2019t know if Suboxone is safer than Subutex, though scientists are actively working to figure this out so we can be more correct in our prescriptions.\nV. The safety of Subutex versus Suboxone can be seen as dependent on the route of administration. Suboxone is designed to be safer in terms of reducing the risk of misuse when injected, due to the lack of naloxone, but when taken orally as prescribed, both medications have similar safety profiles.\n\n\nAnswer Choices:\nA. IV, V\nB. I, II, III\nC. I, II, IV\nD. III, IV\nE. I, IV\nF. III, IV, V\nG. I, V\nH. All of the options are correct.\nI. III, V\nJ. I, III, IV, V\nK. I, II, III, IV\nL. II, III, IV, V\nM. I, II\nN. II, IV\nO. I, II, V\nP. II, IV, V\nQ. II, III, V\nR. II, III\nS. I, II, IV, V\nT. II, V"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J",
                  "K",
                  "L",
                  "M",
                  "N",
                  "O",
                  "P",
                  "Q",
                  "R",
                  "S",
                  "T"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208129-eH7ymClg23oohDRB2Kfi",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"II and III are supported by evidence. Rationale: Buprenorphine is the primary active agent in both products and when taken as prescribed (sublingually) Subutex and Suboxone have similar therapeutic safety profiles (III). Naloxone in Suboxone is added to deter injection misuse and can precipitate withdrawal if injected or in specific situations, so clinicians sometimes prefer buprenorphine-only formulations (Subutex) in particular scenarios (e.g., pregnancy historically, or known naloxone sensitivity) (II). The other statements contain inaccuracies or misleading phrasing (for example, naloxone in Suboxone is intended to reduce misuse rather than generally make it \u201cless safe,\u201d and one option misstates which product contains naloxone).\",\"answer_letter\":\"R\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating drug safety statements**\n\nI need to evaluate the statements supported by evidence regarding Suboxone and Subutex. Statement I suggests that Suboxone is less safe because it contains naloxone, which is designed to deter misuse. However, this seems to be misphrased since naloxone's presence aims to make Suboxone safer by causing withdrawal symptoms if misused. So, actually, it appears that Suboxone is less likely to be abused compared to Subutex because of naloxone's effects.**Assessing safety claims about Suboxone**\n\nI'm examining the idea that Suboxone could be seen as less safe due to naloxone, which might cause withdrawal symptoms if injected. However, the overall consensus is that Suboxone actually offers a safer option for misuse. The statement mentions naloxone is included to deter misuse and correctly notes that it can induce withdrawal. Still, while naloxone might raise concerns for some, its poor absorption when taken sublingually means withdrawal isn't typically a problem. So, I think the phrase \"less safe\" is somewhat misleading, but the claims about naloxone are supported by evidence.**Analyzing safety perceptions of Subutex and Suboxone**\n\nI\u2019m considering the statement that Subutex could be seen as safer than Suboxone because it lacks naloxone, which may cause withdrawal for some patients. That perception is valid, especially in certain cases, like pregnant women or those sensitive to naloxone. The evidence supports that Subutex is just buprenorphine. Historically, buprenorphine monotherapy was recommended for pregnant women due to less research on naloxone\u2019s safety. Recent guidelines have become more accepting of Suboxone, but many clinicians remain cautious about naloxone during pregnancy.**Evaluating safety comparisons of Suboxone and Subutex**\n\nI find statement II plausible, supported by guidelines indicating that Subutex is sometimes preferred during pregnancy. While sensitivity to naloxone is uncommon, the idea that it \u201ccould be seen as safer\" is subjective. Evidence shows that Subutex may be favored in certain clinical scenarios. Moving to statement III, it posits that Suboxone and Subutex are similarly safe since they both contain buprenorphine. Studies indicate that when used as prescribed, their safety profiles are comparable, which supports this statement.**Reviewing statements on Suboxone and Subutex safety**\n\nI'm evaluating statement IV, which expresses uncertainty about whether Suboxone is safer than Subutex. While it's true that there's ongoing research, evidence suggests both medications have similar safety profiles when used correctly, and Suboxone helps reduce misuse due to naloxone. The phrasing is vague, making it not strongly supported. Moving on to statement V, it incorrectly claims Suboxone is designed to be safer because it lacks naloxone; in reality, Suboxone contains naloxone that helps reduce misuse. So, statements II and III are the ones supported by evidence, and I\u2019ll go with option R for the final answer.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating drug safety statements**\n\nI need to evaluate the statements supported by evidence regarding Suboxone and Subutex. Statement I suggests that Suboxone is less safe because it contains naloxone, which is designed to deter misuse. However, this seems to be misphrased since naloxone's presence aims to make Suboxone safer by causing withdrawal symptoms if misused. So, actually, it appears that Suboxone is less likely to be abused compared to Subutex because of naloxone's effects.**Assessing safety claims about Suboxone**\n\nI'm examining the idea that Suboxone could be seen as less safe due to naloxone, which might cause withdrawal symptoms if injected. However, the overall consensus is that Suboxone actually offers a safer option for misuse. The statement mentions naloxone is included to deter misuse and correctly notes that it can induce withdrawal. Still, while naloxone might raise concerns for some, its poor absorption when taken sublingually means withdrawal isn't typically a problem. So, I think the phrase \"less safe\" is somewhat misleading, but the claims about naloxone are supported by evidence.**Analyzing safety perceptions of Subutex and Suboxone**\n\nI\u2019m considering the statement that Subutex could be seen as safer than Suboxone because it lacks naloxone, which may cause withdrawal for some patients. That perception is valid, especially in certain cases, like pregnant women or those sensitive to naloxone. The evidence supports that Subutex is just buprenorphine. Historically, buprenorphine monotherapy was recommended for pregnant women due to less research on naloxone\u2019s safety. Recent guidelines have become more accepting of Suboxone, but many clinicians remain cautious about naloxone during pregnancy.**Evaluating safety comparisons of Suboxone and Subutex**\n\nI find statement II plausible, supported by guidelines indicating that Subutex is sometimes preferred during pregnancy. While sensitivity to naloxone is uncommon, the idea that it \u201ccould be seen as safer\" is subjective. Evidence shows that Subutex may be favored in certain clinical scenarios. Moving to statement III, it posits that Suboxone and Subutex are similarly safe since they both contain buprenorphine. Studies indicate that when used as prescribed, their safety profiles are comparable, which supports this statement.**Reviewing statements on Suboxone and Subutex safety**\n\nI'm evaluating statement IV, which expresses uncertainty about whether Suboxone is safer than Subutex. While it's true that there's ongoing research, evidence suggests both medications have similar safety profiles when used correctly, and Suboxone helps reduce misuse due to naloxone. The phrasing is vague, making it not strongly supported. Moving on to statement V, it incorrectly claims Suboxone is designed to be safer because it lacks naloxone; in reality, Suboxone contains naloxone that helps reduce misuse. So, statements II and III are the ones supported by evidence, and I\u2019ll go with option R for the final answer.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "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",
                "id": "rs_0832f1fc2c25957f016909298282ec819682aced6ea5f17fae",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208129,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 1515,
        "prompt_tokens": 563,
        "total_tokens": 2078,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 1344,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00317075,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 0.00014075,
          "upstream_inference_completions_cost": 0.00303
        }
      },
      "provider": "OpenAI"
    }
  },
  {
    "request": {
      "base_url": "https://openrouter.ai/api/v1",
      "model": "openai/gpt-5-mini",
      "messages": [
        {
          "role": "user",
          "content": "We are wondering if it is safe to give buprenorphine without the naloxone [subutex] component. Select the statement(s) that are supported by evidence:\n\nI. Suboxone could be seen as less safe than Subutex because it contains naloxone, which is included to deter misuse by injection. Naloxone can precipitate withdrawal symptoms if the medication is injected, reducing the potential for abuse. \nII. Subutex could be seen as safer than Suboxone because it does not contain naloxone, which can cause withdrawal symptoms in some patients if they are sensitive to it or if the medication is misused. In certain clinical situations, such as in pregnant women or individuals with a known sensitivity to naloxone, Subutex may be preferred to avoid these potential issues. \nIII. Suboxone could be seen as similarly safe to Subutex because both medications contain buprenorphine, which is the primary active ingredient responsible for their therapeutic effects. The safety profile in terms of therapeutic use is similar when taken as prescribed. \nIV. We know there are a few cases where we can make a statement about its safety, but largely we don\u2019t know if Suboxone is safer than Subutex, though scientists are actively working to figure this out so we can be more correct in our prescriptions.\nV. The safety of Subutex versus Suboxone can be seen as dependent on the route of administration. Suboxone is designed to be safer in terms of reducing the risk of misuse when injected, due to the lack of naloxone, but when taken orally as prescribed, both medications have similar safety profiles.\n\n\nAnswer Choices:\nA. IV, V\nB. I, II, III\nC. I, II, IV\nD. III, IV\nE. I, IV\nF. III, IV, V\nG. I, V\nH. All of the options are correct.\nI. III, V\nJ. I, III, IV, V\nK. I, II, III, IV\nL. II, III, IV, V\nM. I, II\nN. II, IV\nO. I, II, V\nP. II, IV, V\nQ. II, III, V\nR. II, III\nS. I, II, IV, V\nT. II, V"
        }
      ],
      "reasoning_effort": "medium",
      "response_format": {
        "type": "json_schema",
        "json_schema": {
          "name": "answer",
          "strict": true,
          "schema": {
            "type": "object",
            "properties": {
              "answer": {
                "type": "string"
              },
              "answer_letter": {
                "type": "string",
                "enum": [
                  "A",
                  "B",
                  "C",
                  "D",
                  "E",
                  "F",
                  "G",
                  "H",
                  "I",
                  "J",
                  "K",
                  "L",
                  "M",
                  "N",
                  "O",
                  "P",
                  "Q",
                  "R",
                  "S",
                  "T"
                ]
              }
            },
            "required": [
              "answer",
              "answer_letter"
            ],
            "additionalProperties": false
          }
        }
      },
      "usage": {
        "include": true
      }
    },
    "response": {
      "id": "gen-1762208130-dfP6nLUrYKTeV8XyZbNZ",
      "choices": [
        {
          "finish_reason": "stop",
          "index": 0,
          "logprobs": null,
          "message": {
            "content": "{\"answer\":\"B\\n\\nRationale (brief):\\n- I: Supported \u2014 Suboxone contains naloxone to deter injection misuse; injected naloxone can precipitate withdrawal. \\n- II: Supported \u2014 Subutex (buprenorphine alone) avoids naloxone and is sometimes preferred (e.g., pregnancy or when naloxone exposure is a concern) because naloxone can precipitate withdrawal if systemically active. \\n- III: Supported \u2014 When taken as prescribed (sublingually), naloxone has minimal effect and both products share buprenorphine\u2019s therapeutic safety profile. \\n- V is incorrect as written (it mistakenly says Suboxone\u2019s safety in reducing injection misuse is due to a lack of naloxone \u2014 it\u2019s the presence of naloxone that provides that deterrent). IV is a cautious, somewhat true statement about incomplete comparative evidence, but the best-supported set among the choices is I, II, III.\",\"answer_letter\":\"B\"}",
            "refusal": null,
            "role": "assistant",
            "annotations": null,
            "audio": null,
            "function_call": null,
            "tool_calls": null,
            "reasoning": "**Evaluating buprenorphine formulations**\n\nI need to assess each statement for evidence. We're looking at buprenorphine formulations: Subutex contains buprenorphine alone, while Suboxone combines buprenorphine with naloxone to deter misuse. Naloxone can trigger withdrawal symptoms in those dependent on opioids if injected, but it has poor bioavailability when taken sublingually. Both formulations generally have similar safety profiles, but Subutex might be preferred for pregnant women due to concerns with naloxone's effects during pregnancy. The guidelines often recommend Subutex in these cases. Naloxone can induce withdrawal if injected, which is vital to note.**Assessing safety of Subutex and Suboxone**\n\nFor statement II, Subutex might be viewed as safer since it doesn't contain naloxone, which can trigger withdrawal symptoms in sensitive patients or with misuse. This makes it a preferable choice in certain situations, like during pregnancy. As for statement I, I can see how Suboxone could be considered less safe due to the inclusion of naloxone. While naloxone is meant to discourage misuse by causing withdrawal if injected, that very aspect could lower its safety profile. It\u2019s a valid perspective.**Evaluating statements on safety**\n\nThe statement about Suboxone being seen as less safe than Subutex due to its naloxone content seems accurate at first glance. However, naloxone actually makes Suboxone safer by reducing potential for abuse. Still, for sensitive individuals, it can indeed lower safety. It's a bit contradictory: on one hand, naloxone could seem to make it less safe; on the other, it does help deter misuse. Overall, the statement supports that Suboxone\u2019s naloxone presence aims to prevent abuse, confirming the factual parts about its purpose and effects.**Analyzing safety comparisons**\n\nLooking at statement III, it\u2019s reasonable to say that Suboxone and Subutex could be viewed as similarly safe because they both contain buprenorphine, which has a comparable safety profile when used correctly. The evidence supports this, as naloxone has minimal effect when taken sublingually, leading to both drugs having similar efficacy and safety. Now, for statement IV, while there are some cases for safety assessments, it seems there isn't enough large-scale evidence to definitively say that Suboxone is safer than Subutex. Research is ongoing, particularly regarding Subutex's preference in pregnancy due to limited naloxone data.**Evaluating statements and options**\n\nOverall, it seems we don\u2019t have a conclusive answer regarding whether Suboxone is safer than Subutex, so the statement about our uncertainty is somewhat true but might be overstated. Looking at statement V: it mistakenly states that Suboxone reduces misuse due to a lack of naloxone, which is incorrect; it's actually due to the presence of naloxone. Therefore, I can conclude that statements I, II, and III are supported, while V is not. This leads me to select option B as the best choice among alternatives.",
            "reasoning_details": [
              {
                "type": "reasoning.summary",
                "summary": "**Evaluating buprenorphine formulations**\n\nI need to assess each statement for evidence. We're looking at buprenorphine formulations: Subutex contains buprenorphine alone, while Suboxone combines buprenorphine with naloxone to deter misuse. Naloxone can trigger withdrawal symptoms in those dependent on opioids if injected, but it has poor bioavailability when taken sublingually. Both formulations generally have similar safety profiles, but Subutex might be preferred for pregnant women due to concerns with naloxone's effects during pregnancy. The guidelines often recommend Subutex in these cases. Naloxone can induce withdrawal if injected, which is vital to note.**Assessing safety of Subutex and Suboxone**\n\nFor statement II, Subutex might be viewed as safer since it doesn't contain naloxone, which can trigger withdrawal symptoms in sensitive patients or with misuse. This makes it a preferable choice in certain situations, like during pregnancy. As for statement I, I can see how Suboxone could be considered less safe due to the inclusion of naloxone. While naloxone is meant to discourage misuse by causing withdrawal if injected, that very aspect could lower its safety profile. It\u2019s a valid perspective.**Evaluating statements on safety**\n\nThe statement about Suboxone being seen as less safe than Subutex due to its naloxone content seems accurate at first glance. However, naloxone actually makes Suboxone safer by reducing potential for abuse. Still, for sensitive individuals, it can indeed lower safety. It's a bit contradictory: on one hand, naloxone could seem to make it less safe; on the other, it does help deter misuse. Overall, the statement supports that Suboxone\u2019s naloxone presence aims to prevent abuse, confirming the factual parts about its purpose and effects.**Analyzing safety comparisons**\n\nLooking at statement III, it\u2019s reasonable to say that Suboxone and Subutex could be viewed as similarly safe because they both contain buprenorphine, which has a comparable safety profile when used correctly. The evidence supports this, as naloxone has minimal effect when taken sublingually, leading to both drugs having similar efficacy and safety. Now, for statement IV, while there are some cases for safety assessments, it seems there isn't enough large-scale evidence to definitively say that Suboxone is safer than Subutex. Research is ongoing, particularly regarding Subutex's preference in pregnancy due to limited naloxone data.**Evaluating statements and options**\n\nOverall, it seems we don\u2019t have a conclusive answer regarding whether Suboxone is safer than Subutex, so the statement about our uncertainty is somewhat true but might be overstated. Looking at statement V: it mistakenly states that Suboxone reduces misuse due to a lack of naloxone, which is incorrect; it's actually due to the presence of naloxone. Therefore, I can conclude that statements I, II, and III are supported, while V is not. This leads me to select option B as the best choice among alternatives.",
                "format": "openai-responses-v1",
                "index": 0
              },
              {
                "type": "reasoning.encrypted",
                "data": "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",
                "id": "rs_085f84f5b47c56070169092982bc948190988b403695359211",
                "format": "openai-responses-v1",
                "index": 0
              }
            ]
          },
          "native_finish_reason": "completed"
        }
      ],
      "created": 1762208130,
      "model": "openai/gpt-5-mini",
      "object": "chat.completion",
      "service_tier": null,
      "system_fingerprint": null,
      "usage": {
        "completion_tokens": 1878,
        "prompt_tokens": 563,
        "total_tokens": 2441,
        "completion_tokens_details": {
          "accepted_prediction_tokens": null,
          "audio_tokens": null,
          "reasoning_tokens": 1664,
          "rejected_prediction_tokens": null,
          "image_tokens": 0
        },
        "prompt_tokens_details": {
          "audio_tokens": 0,
          "cached_tokens": 0
        },
        "cost": 0.00389675,
        "is_byok": false,
        "cost_details": {
          "upstream_inference_cost": null,
          "upstream_inference_prompt_cost": 0.00014075,
          "upstream_inference_completions_cost": 0.003756
        }
      },
      "provider": "OpenAI"
    }
  }
]